A randomized double-blind placebo controlled 3-arm multicenter phase

Recruiting

99 years or below

All

1 Location

Brief description of study

This is a 52 wk, randomized, double-blind study to demonstarte the clinical efficacy, safety, and tolerability of ianalumab compared to placebo in patients with active Sjogren's syndrome. Pts will receive a subcutaneous injection of ianalumab/placebo monthly, in addition to salivary flow assessments, blood and urine sampling, PROs, and optional assessments for cognitive function.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Medical Research
Age: 99 years or below
Gender: All

Updated on 14 Jun 2023. Study ID: 852128

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

A randomized double-blind placebo controlled 3-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjogren's syndrome (NEPTUNUS-2)

Brief description of study

Eligibility of study

Find a site

Interested in the study